There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients' lives. However, there are other kinds of melanoma not ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

The latest results from the CROWN study didn’t just confirm that lorlatinib (Lorbrena) works well; this study revealed something almost unheard of in advanced lung cancer. At the ASCO 2026 meeting, ...

A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC). Prior ...

Alecensa reduced death risk by 22% compared to Xalkori in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. The study was not powered for OS, resulting in ...

Good morning, and welcome to Nuvalent's conference call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotechnology firm Nuvalent said Monday that its drug for a genetically defined type of lung cancer shrank tumors in ...

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness. Patients who are newly diagnosed ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors, including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...